PACT Pharma Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$200M
Industry:Pharma
Founded:N/A
Lead Investor(s):GV

City Ranking

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • PACT Pharma's estimated annual revenue is currently $33.2M per year.
  • PACT Pharma received $95.0M in venture funding in May 2018.
  • PACT Pharma's estimated revenue per employee is $201,000
  • PACT Pharma's total funding is $200M.

Employee Data

  • PACT Pharma has 165 Employees.
  • PACT Pharma grew their employee count by 90% last year.
  • PACT Pharma currently has 48 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$38.6M192N/AN/A-N/A
#2
$15.3M763%N/A-N/A
#3
N/A125N/AN/A-N/A
#4
$13.1M6523%N/A-N/A
#5
$78.8M392N/AN/A-N/A
#6
$53.1M264N/AN/A-N/A
#7
$59.5M296N/AN/A-N/A
#8
$10.1M504%N/A-N/A
#9
$13.5M6720%N/A-N/A
#10
$62.1M30910%N/A-N/A
Missing a competitor? Contribute!?
Submit

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT's vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient's cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient's own blood to produce PACT's therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient's cancer cells.

keywords:N/A

165

Number of Employees

$33.2M

Revenue (est)

48

Current Jobs

90%

Employee Growth %

$200M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

PACT Pharma News

09/03/2019 - PACT Pharma says it's perfected the tech to select ...

With backing from the Parker Institute for Cancer Immunotherapy, Cristina Puig-Saus led the study at UCLA, where PACT co-founder Antoni ...

09/08/2019 - A personalized CAR-T to attack every solid tumor? Pact ...

Pact Pharma is developing a method for taking T cells from patients with solid tumors and engineering them to be able to recognize and attack ...

09/03/2019 - Sun Pharma signs global licensing pact with CSIR-IICT for patents

Sun Pharmaceutical Industries on Wednesday said it has entered into a global licensing pact with Hyderabad-based CSIR Indian Institute of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
N/A170N/AN/A-N/A
#2
$27.6M17835%$347M-N/A
#3
$33.8M188N/AN/A-N/A
#4
N/A188N/AN/A-N/A
#5
$50.7M20228%N/A-N/A

PACT Pharma Funding

DateAmountRoundLead InvestorsReference
2018-05-30$95.0MUndisclosedGVArticle